Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
victoria.woodcock@oncology.ox.ac.uk

Victoria Woodcock

Honorary Senior Clinical Researcher

Recent publications

Cytomegalovirus infection protects against metastatic melanoma and modulates oncological outcome and toxicity to checkpoint immunotherapy

Milotay G. et al, (2024)

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer.

Woodcock VK. et al, (2023), BJUI Compass, 4, 322 - 330

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.

Taylor CA. et al, (2022), Nat Med, 28, 2592 - 2600

Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors

(2018), Annals of Oncology

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

Woodcock VK. et al, (2018), Br J Cancer, 118, 770 - 776